Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Hao Wang, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe, Frederique Jantet-Blaudez, Sarah Begue, Sophie Gimenez-Fourage & Anke Pagnon. (2021) Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial. Human Vaccines & Immunotherapeutics 17:7, pages 2107-2116.
Read now
Read now
Dieudonné Buh Kum, Robbert Boudewijns, Ji Ma, Niraj Mishra, Dominique Schols, Johan Neyts & Kai Dallmeier. (2020) A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice. Emerging Microbes & Infections 9:1, pages 520-533.
Read now
Read now
Stephen J. Thomas & In-Kyu Yoon. (2019) A review of Dengvaxia®: development to deployment. Human Vaccines & Immunotherapeutics 15:10, pages 2295-2314.
Read now
Read now
Jedhan Ucat Galula, Gielenny M. Salem, Gwong-Jen J. Chang & Day-Yu Chao. (2019) Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?. Human Vaccines & Immunotherapeutics 15:10, pages 2328-2336.
Read now
Read now
Ngoc Huu Tran, Danaya Chansinghakul, Chia Yin Chong, Chian Yong Low, Lynette P. Shek, Chan Quang Luong, Carina Frago, T. Anh Wartel, Sunny Sun, Anna Skipetrova & Alain Bouckenooghe. (2019) Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials. Human Vaccines & Immunotherapeutics 15:10, pages 2315-2327.
Read now
Read now
Bruno Guy, Fernando Noriega, R. Leon Ochiai, Maïna L’azou, Valentine Delore, Anna Skipetrova, François Verdier, Laurent Coudeville, Stephen Savarino & Nicholas Jackson. (2017) A recombinant live attenuated tetravalent vaccine for the prevention of dengue. Expert Review of Vaccines 16:7, pages 671-684.
Read now
Read now
Laura Rivino. (2016) T cell immunity to dengue virus and implications for vaccine design. Expert Review of Vaccines 15:4, pages 443-453.
Read now
Read now
Jian Hang Lam, Li Ching Ong & Sylvie Alonso. (2016) Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?. Expert Review of Vaccines 15:4, pages 483-495.
Read now
Read now
Douglas G Widman & Ralph S Baric. (2015) Dengue virus envelope protein domain I/II hinge: a key target for dengue virus vaccine design?. Expert Review of Vaccines 14:1, pages 5-8.
Read now
Read now
Articles from other publishers (37)
Véronique Corbière, Eleonora E. Lambert, Marine Rodesch, Jacqueline A. M. van Gaans-van den Brink, Alicja Misiak, Elles Simonetti, Anne Van Praet, Audrey Godefroid, Dimitri A. Diavatopoulos, Cécile A. C. M. van Els & Françoise Mascart. (2023) A semi high-throughput whole blood-based flow cytometry assay to detect and monitor Bordetella pertussis-specific Th1, Th2 and Th17 responses. Frontiers in Immunology 14.
Crossref
Crossref
Heather Friberg, Morgan Gargulak, Amanda Kong, Leyi Lin, Luis J. Martinez, Alexander C. Schmidt, Robert M. Paris, Richard G. Jarman, Clemente Diaz, Stephen J. Thomas, Philippe Moris & Jeffrey R. Currier. (2022) Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults. npj Vaccines 7:1.
Crossref
Crossref
Li Qi, Yanqing Sun, Michal Juraska, Zoe Moodie, Craig A. Magaret, Fei Heng, Lindsay N. Carpp & Peter B. Gilbert. (2022) Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia. Vaccine 40:41, pages 5912-5923.
Crossref
Crossref
Diana Leticia Coronel-Martinez, Juliana Park, Eduardo López-Medina, María Rosario Capeding, Andrés Angelo Cadena Bonfanti, María Cecilia Montalbán, Isabel Ramírez, María Liza Antoinette Gonzales, Betzana Zambrano, Gustavo Dayan, Zhenghong Chen, Hao Wang, Matthew Bonaparte, Andrey Rojas, Jenny Carolina Ramírez, Mae Ann Verdan & Fernando Noriega. (2022) Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9–50 years: a randomised, controlled, phase 2, non-inferiority study. The Lancet Infectious Diseases 22:6, pages 901-911.
Crossref
Crossref
Helton C. Santiago, Tertuliano A. Pereira-Neto, Marcela H. Gonçalves-Pereira, Ana C. B. Terzian & Anna P. Durbin. (2022) Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model. Pathogens 11:3, pages 294.
Crossref
Crossref
Gabriela Paz-Bailey, Laura Adams, Joshua M. Wong, Katherine A. Poehling, Wilbur H. Chen, Veronica McNally, Robert L. Atmar & Stephen H. Waterman. (2021) Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR. Recommendations and Reports 70:6, pages 1-16.
Crossref
Crossref
Wen-Hung Wang, Aspiro Nayim Urbina, Max R. Chang, Wanchai Assavalapsakul, Po-Liang Lu, Yen-Hsu Chen & Sheng-Fan Wang. (2020) Dengue hemorrhagic fever – A systemic literature review of current perspectives on pathogenesis, prevention and control. Journal of Microbiology, Immunology and Infection 53:6, pages 963-978.
Crossref
Crossref
Annie Elong Ngono, Thasneem Syed, Anh-Viet NguyenJose Angel Regla-NavaMercylia SusantonoDarina Spasova, Allison Aguilar, Melissa WestJessica Sparks, Andrew Gonzalez, Emilie BrancheJason L. DeHart, Jerel Boyd Vega, Priya Prakash KarmaliPadmanabh ChivukulaKurt Kamrud, Parinaz AliahmadNathaniel Wang & Sujan Shresta. (2020)
CD8
+
T cells mediate protection against Zika virus induced by an NS3-based vaccine
. Science Advances 6:45.
Crossref
Crossref
Gustavo H. Dayan, Edith Langevin, Remi Forrat, Betzana Zambrano, Fernando Noriega, Carina Frago, Alain Bouckenooghe, Tifany Machabert, Stephen Savarino & Carlos A. DiazGranados. (2020) Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus. Vaccine 38:41, pages 6472-6477.
Crossref
Crossref
Josilene Ramos Pinheiro-Michelsen, Rayane da Silva Oliveira Souza, Itana Vivian Rocha Santana, Patrícia de Souza da Silva, Erick Carvalho Mendez, Wilson Barros Luiz & Jaime Henrique Amorim. (2020) Anti-dengue Vaccines: From Development to Clinical Trials. Frontiers in Immunology 11.
Crossref
Crossref
Lucas Wilken & Guus F. Rimmelzwaan. (2020) Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?. Pathogens 9:6, pages 470.
Crossref
Crossref
Eleonora E. Lambert, Véronique Corbière, Jacqueline A. M. van Gaans-van den Brink, Maxime Duijst, Prashanna Balaji Venkatasubramanian, Elles Simonetti, Martijn Huynen, Dimitri D. Diavatopoulos, Pauline Versteegen, Guy A. M. Berbers, Françoise Mascart & Cécile A. C. M. van Els. (2020) Uncovering Distinct Primary Vaccination-Dependent Profiles in Human Bordetella pertussis Specific CD4+ T-Cell Responses Using a Novel Whole Blood Assay. Vaccines 8:2, pages 225.
Crossref
Crossref
Niraj Mishra, Robbert Boudewijns, Michael Alexander Schmid, Rafael Elias Marques, Sapna Sharma, Johan Neyts & Kai Dallmeier. (2020) A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies. mBio 11:2.
Crossref
Crossref
Bruno Guy, Eng Eong Ooi, Jose Ramos-Castañeda & Stephen J. Thomas. (2020) When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection?. Vaccines 8:2, pages 174.
Crossref
Crossref
Jinsheng Wen & Sujan Shresta. (2019) Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?. Current Opinion in Immunology 59, pages 1-8.
Crossref
Crossref
Peter B. GilbertYing HuangMichal JuraskaZoe MoodieYouyi FongAlexander LuedtkeYingying ZhuangJason ShaoLindsay N. CarppNicholas JacksonLaurent ChambonneauAlain BouckenoogheBetzana ZambranoCarina FragoSophie PallardyFernando Noriega. (2019) Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. The American Journal of Tropical Medicine and Hygiene 101:1, pages 164-179.
Crossref
Crossref
Annie Elong Ngono & Sujan Shresta. (2019) Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development. Frontiers in Immunology 10.
Crossref
Crossref
Guangyu Li, Cody Teleki & Tian Wang. (2018) Memory T Cells in Flavivirus Vaccination. Vaccines 6:4, pages 73.
Crossref
Crossref
Bruno Guy. (2018) Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?. Cold Spring Harbor Perspectives in Biology 10:6, pages a029462.
Crossref
Crossref
Zoe Moodie, Michal Juraska, Ying Huang, Yingying Zhuang, Youyi Fong, Lindsay N Carpp, Steven G Self, Laurent Chambonneau, Robert Small, Nicholas Jackson, Fernando Noriega & Peter B Gilbert. (2018) Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America. The Journal of Infectious Diseases 217:5, pages 742-753.
Crossref
Crossref
Anuja Mathew. 2018. Dengue and Zika: Control and Antiviral Treatment Strategies. Dengue and Zika: Control and Antiviral Treatment Strategies
251
264
.
Joseph Torresi, Peter C Richmond, Leon G Heron, Ming Qiao, Joanne Marjason, Linda Starr-Spires, Diane van der Vliet, Jing Jin, T Anh Wartel & Alain Bouckenooghe. (2017) Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding. The Journal of Infectious Diseases 216:7, pages 834-841.
Crossref
Crossref
Noemia S. Lima, Morgane Rolland, Kayvon Modjarrad & Lydie Trautmann. (2017) T Cell Immunity and Zika Virus Vaccine Development. Trends in Immunology 38:8, pages 594-605.
Crossref
Crossref
Wen-Yang Tsai, Hong-En Lin & Wei-Kung Wang. (2017) Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development. Frontiers in Microbiology 8.
Crossref
Crossref
Laura Rivino & Mei Qiu Lim. (2017)
CD4
+
and CD8
+
T-cell immunity to Dengue - lessons for the study of Zika virus
. Immunology 150:2, pages 146-154.
Crossref
Crossref
Lesley J. Scott. (2016) Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease. Drugs 76:13, pages 1301-1312.
Crossref
Crossref
Sophia Gailhardou, Anna Skipetrova, Gustavo H. Dayan, John Jezorwski, Melanie Saville, Diane Van der Vliet & T. Anh Wartel. (2016) Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials. PLOS Neglected Tropical Diseases 10:7, pages e0004821.
Crossref
Crossref
Bruno GuyJean LangMelanie SavilleNicholas Jackson. (2016) Vaccination Against Dengue: Challenges and Current Developments. Annual Review of Medicine 67:1, pages 387-404.
Crossref
Crossref
Bruno Guy & Nicholas Jackson. (2015) Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nature Reviews Microbiology 14:1, pages 45-54.
Crossref
Crossref
Bruno Guy, Olivier Briand, Jean Lang, Melanie Saville & Nicholas Jackson. (2015) Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward. Vaccine 33:50, pages 7100-7111.
Crossref
Crossref
Alan L. Rothman, Jeffrey R. Currier, Heather L. Friberg & Anuja Mathew. (2015) Analysis of cell-mediated immune responses in support of dengue vaccine development efforts. Vaccine 33:50, pages 7083-7090.
Crossref
Crossref
Jacky Flipse & Jolanda M. Smit. (2015) The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response. PLOS Neglected Tropical Diseases 9:6, pages e0003749.
Crossref
Crossref
Patricia Bourguignon, Frédéric Clément, Frédéric Renaud, Vivien Le Bras, Marguerite Koutsoukos, Wivine Burny, Philippe Moris, Clarisse Lorin, Alix Collard, Geert Leroux-Roels, François Roman, Michel Janssens & Linos Vandekerckhove. (2014) Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naïve HIV-1-infected patients. Journal of Immunological Methods 414, pages 1-10.
Crossref
Crossref
Jianchun Wei, Hui Chen & Jing An. (2014) Recent progress in dengue vaccine development. Virologica Sinica 29:6, pages 353-363.
Crossref
Crossref
Anuja Mathew, Elizabeth Townsley & Francis A Ennis. (2014) Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections. Future Microbiology 9:3, pages 411-425.
Crossref
Crossref
Alan L. Rothman, Carey L. Medin, Heather Friberg & Jeffrey R. Currier. (2013) Immunopathogenesis versus Protection in Dengue Virus Infections. Current Tropical Medicine Reports 1:1, pages 13-20.
Crossref
Crossref
Eduardo J. M. Nascimento, Robbie B. Mailliard, Asif M. Khan, John Sidney, Alessandro Sette, Nicole Guzman, Michael Paulaitis, Andréa Barbosa de Melo, Marli T. Cordeiro, Laura V. G. Gil, Françoir Lemonnier, Charles Rinaldo, J. Thomas August & Ernesto T. A. Marques. (2013) Identification of Conserved and HLA Promiscuous DENV3 T-Cell Epitopes. PLoS Neglected Tropical Diseases 7:10, pages e2497.
Crossref
Crossref